Drug Discovery Featured Articles & Applications

  1. Relative Cost Models: A Better Way To Look At Risk/Reward During Early Drug Development?
    10/14/2015

    Trying to add value while maintaining cost-effectiveness in drug development is like a game of chicken. When faced with two highly important but opposing directives, we often wait to see who blinks first: will it be the cautious development team or the hard-driving discovery team?

  2. Best Practices In Supply Chain Management: A CMO Perspective
    9/16/2015

    Supply chain management has advanced rapidly over the past decade, evolving from what was once dubbed “materials management” into the essential glue that binds all aspects of a business’ internal and external collaborations.

  3. Key Considerations When Choosing A Partner For Drug Discovery
    9/11/2015

    The changes in the economic landscape and pipelines over the last 10-15 years have resulted in drug developers in companies of all sizes to take a hard look at their strategy and operations.

  4. Big Data Analytics: The Next Evolution In Drug Development
    7/23/2015

    The drug development process is complex and financially risky. A recent study by The Tufts Center for the Study of Drug Development estimates the cost of developing a new drug at $2.6 billion and suggests that costs of drug development are rising with a compound annual growth rate of 8.5 percent.

  5. Genomics & Tissue Phenomics: Taking A Dual Approach To Drug Development
    6/9/2015

    It can be said that 2014 was the year of genomics. The industry saw several new startups in the area, and Google's venture into the genomics market made a big splash. However, in 2015 the industry is expected to look beyond genes and focus on a dual approach to drug development leveraging data from both the genes and the tissue, particularly in oncology.

  6. Microbiome Research: The New Horizon In Therapeutic Value Creation
    5/19/2015

    There are many potential causes of microbial imbalance (dysbiosis) in adulthood, including repeated and inappropriate exposure to antibiotics in earlier years, alcohol misuse, or an inappropriate diet.  Balancing the intestinal microbiome is a logical approach to preventing or reversing diseases caused by dysbiosis. 

  7. Remote SDV/SDR: Alternatives To Redact/Fax
    4/30/2015

    As part of their risk-based monitoring strategy, many sponsors and CROs are using remote techniques to conduct source data review and verification (SDR and SDV).The best implementations out there actually streamline activities at both ends, both for sponsors/CROs and for study sites.

  8. Dermal Toxicology: A Multifaceted Approach To Meet Today’s Research Needs
    3/3/2015

    Developing a dermal NCE generally follows the same path as other small molecule NCEs administered orally or systemically, except that the dermal route is used in a non-rodent model.

  9. Single Molecule Measurement: Best Practices In Biomarker Detection
    1/7/2015

    By Mark Roskey, Vice President and General Manager, Applications and Reagents 

    The human genome encodes thousands of secreted proteins, each of which is an actor in the delicate biochemical balance of diagnostics. Even a slight change in any one of these proteins can mean the difference between sickness and health. Such a change also provides a critical window into the body and helps to direct diagnosis and treatment, however, the vast majority of secreted proteins are present in concentrations well below what conventional technologies can measure, and their role in human health is poorly understood. Researchers have continued to seek ways to detect and diagnose earlier and more accurately through protein detection, and have been unsuccessful at doing so – until now.

  10. Getting The Most Out Of Your Viral Clearance Study
    11/5/2014

    By John Zehmer, PhD, Senior Scientist and Study Director at BioReliance

    Conducting a viral clearance study is an important step on the road toward getting your biomolecule into the clinic and on its way to becoming a drug. However, since most companies do not have the systems in place to support a regulated virological study of this kind, this will likely mean engaging a contract research organization (CRO) as a partner. The keys to meeting your goals are solid planning and good communication between your group and your CRO partner. This article provides a high-level review of these processes and will aid in planning for a successful study.